"Antibodies, Monoclonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies produced by a single clone of cells.
| Descriptor ID |
D000911
|
| MeSH Number(s) |
D12.776.124.486.485.114.224 D12.776.124.790.651.114.224 D12.776.377.715.548.114.224
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal".
This graph shows the total number of publications written about "Antibodies, Monoclonal" by people in this website by year, and whether "Antibodies, Monoclonal" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 4 | 11 | 15 |
| 1997 | 4 | 6 | 10 |
| 1998 | 6 | 16 | 22 |
| 1999 | 10 | 18 | 28 |
| 2000 | 7 | 12 | 19 |
| 2001 | 13 | 20 | 33 |
| 2002 | 11 | 14 | 25 |
| 2003 | 16 | 16 | 32 |
| 2004 | 23 | 16 | 39 |
| 2005 | 25 | 18 | 43 |
| 2006 | 26 | 16 | 42 |
| 2007 | 30 | 13 | 43 |
| 2008 | 20 | 19 | 39 |
| 2009 | 30 | 19 | 49 |
| 2010 | 35 | 21 | 56 |
| 2011 | 19 | 11 | 30 |
| 2012 | 17 | 11 | 28 |
| 2013 | 19 | 8 | 27 |
| 2014 | 17 | 12 | 29 |
| 2015 | 13 | 8 | 21 |
| 2016 | 15 | 7 | 22 |
| 2017 | 27 | 11 | 38 |
| 2018 | 24 | 15 | 39 |
| 2019 | 17 | 10 | 27 |
| 2020 | 15 | 15 | 30 |
| 2021 | 12 | 19 | 31 |
| 2022 | 4 | 25 | 29 |
| 2023 | 4 | 18 | 22 |
| 2024 | 16 | 7 | 23 |
| 2025 | 12 | 7 | 19 |
| 2026 | 8 | 3 | 11 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Monoclonal" by people in Profiles.
-
Outcomes and Predictors of Sustained Response After Dose Tapering of Targeted Therapies in Moderate-to-Severe Atopic Dermatitis: A Systematic Review. Am J Clin Dermatol. 2026 Nov; 27(6):1161-1175.
-
Monoclonal antibodies inhibiting MMP-9 activity alleviate peripheral neuropathy in diabetic mice. Sci Transl Med. 2026 Sep 09; 18(866):eadw3558.
-
Time-dependent divergence in infection risks among patients with multiple sclerosis treated with fumarates versus anti-CD20 monoclonal antibodies. Mult Scler. 2026 Oct; 32(12):1302-1314.
-
Lipid Nanoparticle-Encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36? plus Durvalumab Induces an Immunostimulatory Effect within the Tumor Microenvironment in Patients with Advanced Solid Tumors. Clin Cancer Res. 2026 Aug 14; 32(16):3493-3505.
-
Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE. Blood Adv. 2026 07 14; 10(13):4541-4550.
-
Corticosteroid-sparing effects of risankizumab versus ustekinumab in patients with moderately to severely active Crohn's disease: post hoc results from the phase 3b SEQUENCE trial. J Crohns Colitis. 2026 Jul 07; 20(7).
-
Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial. Lancet Oncol. 2026 Aug; 27(8):1043-1056.
-
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. N Engl J Med. 2026 Apr 02; 394(13):1257-1269.
-
Comparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn's Disease: A Systematic Literature Review and Network Meta-Analysis. Adv Ther. 2026 03; 43(3):1016-1033.
-
Pediatric Infectious Diseases Physicians' Preferences for Management of Clostridioides difficile Infection: An Emerging Infections Network Survey. J Pediatric Infect Dis Soc. 2026 Jan 17; 15(1).